This may be good news for partners Mylan and Biocon: Two bills are circulating on Capitol Hill that can alter the transition of insulins to biologic agents in March 2020. However, the timing for passage of these bills is questionable. The Senate’s Affordable Insulins Approval Now Act (S.2103), a bipartisan bill that was introduced by … Continue reading New Legislative Proposals Offer Hope to Insulin Follow-on Manufacturers →